Interaction between JWH133-induced Antinociception and two

Transkrypt

ƱŚºŬƳŻƾºĪƃżěƭƺºƬƗƵŚĮºƄƳřŵƾƄºƷƹĦěƾºưƬƗƽƶƬºŬƯ
Downloaded from zums.ac.ir at 11:25 IRST on Wednesday March 8th 2017
ÏÏŚţÎÎšŚŰƠƇÎÐÕÕƱŚŤƀŝŚţƽƵŹŚưƃ
ÎƽƵŹ
ƹŵ
żǀģŚƳŹŚǀƀŝƹƩƺưƘƯƽŚƷŻƹŵƹJWH133ŻřƪƇŚůƽŵŹŵƾŝźŧřƪųřŶţƾſŹźŝ
ƽŹƺſƁƺƯŹŵŜǀƀƧƺƨƬſ
èƽźǀĮƳŚƸūƱĦǀŝźŤƧŵèŢſŵƲƿŹŻŚƋŹŶưŰƯźŤƧŵçŪƬƧƾŗŚƋŹƵŵƺſźŤƧŵæƾƳŚƯźƸƣřźƷŻźŤƧŵ
éƽźƠƘūŚƋŹŶưŰƯźŤƧŵ
[email protected]ƽĥƺƫƺƧŚƯŹŚƟƹƽĥƺƫƺƿżǀƟƵƹźĭƾƨƃżěƽƵŶƨƄƳřŵ
ƾƨƃżěƭƺƬƗƵŚĮƄƳřŵƱŚŬƳŻƩƺŘƀƯƽƵŶƴƀƿƺƳ
ííëçíƁźƿŸěííëîŢƟŚƿŹŵ
ƵŶǀƨģ
ŹŚºƸƯƦºƿŜǀƀºƧƺƨƬſŢſřŵŹŵŶƋźŧřŶūřƹƶƧŢſřƵŶƃƶŤųŚƴƃçƽŶǀŗƺƴǀŝŚƳŚƧƽƵŶƳźǀĭŢƀǀƳƺĭōƱřƺƴƗƶŝJWH133ƝŶƷƹƶƴǀƯŻ
źºŧřƵřźºưƷƶºŝŻŚƳĦǀƀºƧƺƬƨǀſźǀƀºƯŹŵǇŚºưŤůřƹŵŹřŵƾƴǀƫŚºŝŵźŝŹŚƧŵŹŵŶƋƽƹŹřŵƦƿƱřƺƴƗƶŝçŻŚƳĦǀƀƧƺƬƨǀſƮƿżƳōƾƇŚƈŤųřƽƵŶƴƴƧ
JWH133ŻřƪºƇŚůƽŵŹŵƾŝźŝ
żǀģŚƳƹƩƺưƘƯŻƹŵŚŝŜǀƀƧƺƨƬſźŧřƾſŹźŝźƋŚůƽƶƘƫŚƐƯŻřƝŶƷŶƿŚưƳƾƯŢƫŚųŵŚƷŶǀŗƺƴǀŝŚƳŚƧƽŵŹŵƾŝ
ŢſřƵŵƺŝ
ƭźĭƺºƬǀƧźºŝƭźºĭƺƳŚƳêåƹçêżǀģŚƳŹŚǀƀŝƹƭźĭƺƬǀƧźŝƭźĭƾƬǀƯçååŚţêåƩƺưƘƯŻƹŵƢƿŹżţƾƫŚưŤůřƪųřŶţƶƘƫŚƐƯƲƿřŹŵƾſŹźŝƁƹŹ
ŢſřƵŶƃƾſŹźŝƽŹƺſƁƺƯŹŵƲǀƫŚƯźƟƱƺƯŻōŻřƵŵŚƠŤſřŚŝJWH133ƾƣŚƠƇƪųřŵƢƿŹżţŻřƪƇŚůƽŵŹŵƾŝźŧřƽƹŹźŝŜǀƀƧƺƨƬſ
żǀģŚƳŹŚǀƀŝŻƹŵƹƭźĭƺƬǀƧźŝƭźĭƾƬǀƯçååŚţêåƩƺưƘƯŻƹŵŵřŵƱŚƄƳƽŵŹŵƾŝźŧřƲǀƫŚƯźƟƱƺƯŻōƦƿƽƶƬůźƯŹŵƎƤƟJWH133ŚƷƶŤƟŚƿ
ŵƺưƳŢƿƺƤţřŹJWH133ƽŵŹŵƾŝźŧř
ƭźĭƺƬǀƧźŝƭźĭƺƳŚƳ
êåŚţçêŜǀƀƧƺƨƬſ
ŜǀƀºƧƺƨƬſƩƺưƘƯŻƹŵƲưƋŹŵƹŢſřƵŵřŵŹřźƣźǀŧŚţŢŰţřŹJWH133ŻřƪƇŚůƽŵŹŵƾŝźŧřŜǀƀƧƺƨƬſƶƧŶſŹƾƯźƔƳƶŝƽźǀĭƶŬǀŤƳ
ŢſřƵŵƺŝŹřŸĭźǀŧŚţ
ƽŹƺſƁƺƯŹŵƲǀƫŚƯźƟƱƺƯŻōŹŵƹŹřŵƲƿřżǀģŚƳŹŚǀƀŝŻƹŵŚŝŵŚƌţŹŵ
ƽŹƺſƁƺƯƹżǀģŚƳŻƹŵŜǀƀƧƺƨƬſƽŵŹŵƾŝ
JWH133ƽŶǀƬƧƱŚĭĥřƹ
źºººŧřŶºººūřƹŵřŻƱƹŹŵƽŚƷŶºººǀŗƺƴǀŝŚƳŚƧæŵƺºººưƳƵŹŚºººƃř
ƶƯŶƤƯ
ƽŚƷŶºƴƿřźƟŻřƽŵřŶºƘţŹŵ ŵřŻƱƹŹŵƽŶºǀŗƺƴǀŝŚƳŚƧƮŤƀǀſ
źǀŧŚºţŻřƾƄºŴŝƪƣřŶºůŶºƃŚŝƾºƯ ŚƷŶǀŗƺǀěƹřŚŝƶƀƿŚƤƯƪŝŚƣ
ƶºƔƟŚůƹƽźǀĭŵŚºƿƾŞƈƗƽŚƷƾŬƳŚǀƯƽŻŚſŚƷŹƪƿŶƘţŵŹŵ
ƱŚŬƳŻƾƨƃżěƭƺƬƗƵŚĮƄƳřŵƾƯƺưƗƦƃżěæ
ƱŚŬƳŻƾƨƃżěƭƺƬƗƵŚĮƄƳřŵŹŚƿŵŚŤſřƽĥƺƫƺƧŚƯŹŚƟƾƈƈŴţƽřźŤƧŵé
źǀŧŚºţƱřżºǀƯƹšŹŶºƣźºƔƳŻřźºŧřƲºƿřƶºƧŶƴŤƀƷƽŵŹŵƾŝ
žºůƥŹŵƶºŝƱřƺºţƾºƯŚºƸƳōƶƬưūŻřŵŹřŵƂƤƳƦƿĥƺƫƺƿżǀƟ
ƱǈǀĭƾƨƃżěƭƺƬƗƵŚĮƄƳřŵƾƬųřŵśŚƈƗřƾƈƈŴţƽƺŬƄƳřŵƾƯƺưƗƦƃżěç
ƱřźƸţƾƨƃżěƭƺƬƗƵŚĮƄƳřŵŵŚŤſřƽĥƺƫƺƧŚƯŹŚƟƾƈƈŴţƽřźŤƧŵè
JWH133ŻřƪƇŚůƽŵŹŵƾŝźŧřƪųřŶţƾſŹźŝ
ƾſŹźŝƁƹŹ
źºƳƽŹƺºſƽŚƷƁƺƯ
ƢǀƤŰţƲƿřŹŵƾƷŚĮƄƿŚƯŻō Ʊřƺǀů
ŹřźººƣƵŵŚƠŤººſřŵŹƺººƯƭźººĭçåéçîîƾºƳŻƹƽƵŵƹŶººŰƯŹŵ
ƾƨǀŤºſǈěƽŚºƷžƠƣŹŵƾƿŚţìƽŚƷƵƹźĭŹŵŚƷƁƺƯ
ŢƟźĭ
ƹƾƿŚƴƃƹŹ ƽƶŤƗŚſ æçƽŚƷƵŹƹŵ
ŚŝPlexiglas ƅƺƈŴƯ
ŵřźººĭƾ
ŤƳŚººſƽƶººūŹŵçç  çšŹřźººůƽƶººūŹŵŚººŝƾƨƿŹŚººţ
źƷ.ŶƃƵŵřŵŵŹřŶƳŚŤſřƽřŸƛƹśōŚƸƳōƶŝŶƳŶƃƵŵřŵƁŹƹźě
ƪºůřźƯƭŚºưţƹŢƟźĭŹřźƣƂƿŚƯŻōŵŹƺƯŹŚŝƦƿƎƤƟƱřƺǀů
ŢŞƣřźƯƹƵŵŚƠŤſřƽřźŝśƺƈƯƽŚƷƁƹŹźŝƢŞƐƴƯƵŶƃƭŚŬƳř
ŵƺŝƾƷŚĮƄƿŚƯŻōšŚƳřƺǀůŻř
ĢƿŹŶºººƫōŚưĮǀº ºſŢƧźºººƃŻřŜǀƀºººƧƺƨƬſƹJWH133
ƵŵŚƠŤºººſřŚºººŝJWH133ƱƺǀƀºººƫƺƯřŶƳŶºººƃƽŹřŶºººƿźų
ŶƿŚƀºººƧŚƠƫƺſƪºººǀŤƯƽŵƹŚƿƺºººſƲºººƛƹŹêƪºººƯŚůŻř
ƾººƨưƳƭźººſŹŵ[Dimethylsulfoxide, (DMSO)]
ƵŵŚºƯōƾºĪưƳƭźºſŹŵŜǀƀºƧƺƨƬſƱƺǀƀºƳŚĜſƺſƹŶƃƶǀƸţ
ƾƣŚƠºƇƪºųřŵšŹƺºƇƶŝƲǀƫŚƯźƟżūƶŝŚƷƹŹřŵƭŚưţŶƿŵźĭ
ŹŵŶºƃƵŵŚƠŤºſřƂƿŚƯŻōƵƹźĭźƷŹŵƁƺƯŢƠƷŶƃƢƿŹżţ
ŶºƃƾºƯƭŚºŬƳřƾƣŚƠºƇƪºųřŵŵŶƘŤƯšŚƤƿŹżţƶƧƾţŚƄƿŚƯŻō
ƾºưŬůźŨƧřŶºůƱřƺºǀůźƷƶƧŵƺŝƵŶƃƮǀƔƴţƽŹƺƏŚƷŻƹŵ
ƽźºſƦºƿŹŵŶƿŚưƳŢƟŚƿŹŵƭźĭƺƬǀƧŹŵƭźĭƾƬǀƯæåƩŵŚƘƯ
ƭźĭƺƬǀƧźŝźŤǀƫƾƬǀƯæåŶƷŚƃƵƹźĭŹŵŚƷƁƺƯ
šŚƄƿŚƯŻōŻř
ƾţŚƠºƇƪųřŵšŹƺƇƶŝJWH133ƪƯŚůŚƿƽĥƺƫƺƿżǀƟƭźſ
ååæƩŚºƯźƳƱƺƯŻōŻřƪŞƣƶƤǀƣŵçêŚƷƁƺƯ
ƽƶǀƤŝƹŢƟŚƿŹŵ
ƪºųřŵšŹƺºƇƶºŝ JWH133ƭźĭƺƬǀĩźŝƭźĭƾ
ƬǀƯæƹåæ
ƽƹŹřŵ šŚƄºƿŚƯŻōŻřƽźĮƿŵƽźſ ŹŵŶƳŵźƧŢƟŚƿŹŵ ƾƣŚƠƇ
ƹæååêåƩƺưƘƯƽŚƷŻƹŵŚŝŚƷƁƺƯƽƹŹźŝřŹŜǀƀƧƺƨƬſ
ƽŚºƷŻƹŵƹƾƣŚƠƇƪųřŵšŹƺƇƶŝƭźĭƺƬǀĩźŝƭźĭƾ
ƬǀƯçåå
ƪºųřŵšŹƺºƇƶºŝƭźĭƺºƬǀĩźŝƭźĭƺƳŚƳêåƹçêƲǀƿŚěŹŚǀƀŝ
ƪººƯŚůŚººŝƵřźººưƷƲǀƫŚººƯźƟƱƺººƯŻōŻřƪººŞƣƶººƤǀƣŵèåƾƣŚƠººƇ
ŻřƭźĭƺººƬǀĩźººŝƭźººĭƾ
ººƬǀƯæƹåæååæŚººƿJWH133
ƱƺºƯŻōŻřƪŞƣƶƤǀƣŵçêƾƣŚƠƇƪųřŵšŹƺƇƶŝJWH133
12
ƩƺƴǀŝŚƳŚƧƹŹŶººǀƷřźŤţƶººŝŵřŻƱƹŹŵƽŚƷŶººǀŗƺƴǀŝŚƳŚƧƽŵŹŵƾººŝ
ŵƺºƃƾƯƵŵřŵŢŞƀƳ
[Tetrahydrocannabinol(THC)]
ƞººƬŤŴƯƽŚººƷƩŶººƯŹŵTHCŻřƪººƇŚůƽŵŹŵƾººŝźººŧřřźºƿŻ
ƽŵŹŵƾººŝƮƀººǀƳŚƨƯçéŢººſřƵŶººƃƂƿŚººƯŻōƾƳřƺººǀů
ƶŤųŚƴºƃƾŝƺºųƶºŝŻƺºƴƷŵřŻƱƹŹŵƽŚƷŶºǀŗƺƴǀŝŚƳŚƧŻřƪƇŚů
ƾƷŚĮƄºººƿŚƯŻōšřŶƷŚƄºººƯŽŚºººſřźŝŚºººƸŤƴƯŢºººſřƵŶƄºººƳ
ƽŵŹŵƾºŝƮƀǀƳŚƨƯŻřšƹŚƠŤƯƮƀǀƳŚƨƯƲƿřƶƧ ŶſŹƾƯźƔƳƶŝ
źºŧřTHCƾƫƺºƨƫƺƯŮƐºſŹŵêŢſŚƷŶǀŗƺǀěřŻřƪƇŚů
ƪƈºŤƯƽƵĦƿƹƽŚƷƵŶƳźǀĭ
ƶŝƩŚƈţřƢƿźƏŻřřŹŵƺųƽŵŹŵƾŝ
ƽŚºƷƵŶºƳźǀĭƱřƺºƴƗƶºŝƶºƧŶºƴƧƾºƯƩŚºưƗřƾºūƲǀŘţƹźěƶŝ
ƽŚºƷƵŶƳźǀĭƹ ëżƜƯŹŵľŚţŶưƗ ƶƧ CB1 æ ƽŶǀŗƺƴǀŝŚƳŚƧ
ìŶºººƳŵźĭƾºººƯŢºººƟŚƿƎǀºººŰƯŹŵľŚţŶºººưƗƶºººƧ CB2
ƵŶºƳźǀĭƹŵźºƷƾƇŚƈºŤųřƽŚºƷŢƀºǀƳƺĭōŵƺºƃƾºƯƶŤųŚƴƃ
ƽŵŶºƘŤƯƽŚºƷŢƀǀƳƺĭōŢſřƵŶƃ ƶŤųŚƴƃ CB2 ƹ CB1 JWH133ŚƸƳōƱŚǀƯŹŵƶƧƵŶƃƶŤųŚſ CB2 ƽƵŶƳźǀĭ ƽřźŝ
íŵŹřŵƵŶƳźǀĭƲƿřƶŝƽŵŚƿŻƪƿŚưţ
ƲǀƫŚºƯźƟƢºƿŹżţŵŹřŶƳŚŤſřƱƺƯŻōŻřƽŵŹŵƾŝźŧřƱŵƺƯŻōƽřźŝ
ƱƺƀººƿƺŝƹŵƹżººǀƳŵƎººſƺţƶººƧŶººƃƵŵŚƠŤººſřƽŶººƬūźƿŻ
žĜºſƹŶºƃƕřŶŝřæîììƩŚſŹŵDenizDubuisson
ŶºƿŵźĭŭǈºƇřæîîçƩŚſŹŵ Tjolsen Ʋƀƫƺūƾţ Ǝſƺţ
ƽŵŹŵƾºŝƮƀºǀƳŚƨƯŻřƾƄºŴŝƪƣřŶºůƶƧƾƿŚŬƳōŻřîƹæå
ŢſřCOXŻŚƳĦǀƀƧƺƬƨǀſźǀƀƯƢƿźƏŻřTHCŻřƪƇŚů
ŜǀƀººƧƺƨƬſƩƺººưƘƯƽŚººƷŻƹŵźººĮƿŵƝźººƏŻřææƹæç
ŹŵƽŵŚƌººŤƯšřźººŧřCOXII ƾŝŚººŴŤƳřŢƀººǀƳƺĭŚŤƳōƦººƿ
ƶºŝƶŤƀºŝřƹƽźǀĭŵŚºƿŹŵƱōƲǀƿŚºěŹŚǀƀºŝƽŚºƷŻƹŵŚŝ ƶƀƿŚƤƯ
ŵƺºŝƝŶƷƹŵƩŚŞƳŵƶŝźƋŚůƽƶƘƫŚƐƯæèŶƳřƶŤƃřŵƲǀƟŹƺƯ
ŻřƪºƇŚůƽŵŹŵƾºŝźºŝŜǀƀºƧƺƨƬſźºŧřƾºſŹźŝƩƹřƝŶƷ
ŻƹŵƞººǀƏƹŵšřźººŧřƽƶƀººƿŚƤƯƭƹŵ
ƝŶººƷƹJWH133
ƹ ƭźĭƺºƬǀƧŹŵƭźĭƾƬǀƯ ƩƺưƘƯ ƽŚƷŻƹŵ ƪƯŚƃ ŜǀƀƧƺƨƬſ
ƪƇŚůƽŵŹŵƾŝźŝƭźĭƺƬǀƧŹŵƭźĭƺƳŚƳżǀģŚƳŹŚǀƀŝƽŚƷŻƹŵ
ŵƺŝJWH133Żř
ÕÕƱŚŤƀŝŚţÓÔƽƵŹŚưƃ
ÎÔƽƵŹƹŵƱŚŬƳŻƾƳŚƯŹŵƾŤƃřŶƸŝšŚƯŶųƹƾƨƃżěƭƺƬƗƵŚĮƄƳřŵƾƄƷƹĦěƾưƬƗƽ
ƶƬŬƯ
13
ƱřŹŚƨưƷƹƾƳŚƯźƸƣřźƷŻźŤƧŵ
šŶºƯƕƺºưŬƯƲǀĮƳŚºǀƯŶºƃ ƶŤƟźĭźƔƳŹŵ ŵŹŵŲſŚěƱřƺƴƗ
ƢºƿŹżţƲǀƫŚƯźƟƁƹŹƶŝŵŹŵƱƺƯŻōŹŵŶƳŵźƧżƿƺŬţƲǀƫŚƯźƟ
ƭƹŵƽƶººƤǀƣŵêåŚºţæêƹƩƹřƶºƬůźƯƱřƺºƴƗƶºŝƩƹřƽƶºƤǀƣŵ
æéƦºƿĥƺƫƺƿżǀƟƹźŤƨƫřƹîƽŹŚºŤƟŹ ƽŚºƷŲºſŚěƽƵŶƳŹřŵ
êŚºţźƠºƇƽŚºƷƱŚƯŻƲǀŝŚƯŚěƲŤƟźĭŻŚĭŚƿƹƱŵŻžǀƫƱŚƯŻ
ƱƺºƯŻōƱōƩŚŞƳŶŝƹƶƟźƐƨƿřƺƳō žƳŚƿŹřƹżǀƫŚƳōƮǀŤƟźĭ źƔƳ
ƾŝŚºƿŻŹřƽřźºŝ Newman–KeulsƩƺºƧƲƯƺºǀƳƾºƬǀưƨţ
žƳŚºƿŹřƹżǀƫŚºƳōŶºƃ ƵŵŚƠŤºſřƹŹřŵƦºƿŻřƪºƇŚůƽŵŹŵƾŝ
ƽřźºŝScheffeƶƠǀºƃƾºƬǀưƨţƱƺƯŻōƱōƩŚŞƳŶŝƹƶƟźƏƹŵ
ƱŚººǀƯƮƀººǀƳƺĭŚŤƳōŚººƿ(synergism)ƮƀººƿĥźƴǀſźººŧřƞƄººƧ
ƵŵŚƠŤºſřŵŹƺºƯJWH133 ƹŜǀƀºƧƺƨƬſƞºƬŤŴƯƽŚƷŻƹŵ
ƾƳŚƯŻƽŹŚƯōƑŚŰƫŻřŚƷƵƹźĭƲǀĮƳŚǀƯƲǀŝšƹŚƠţŢƟźĭŹřźƣ
ŶƯōŢſŶŝ
P<ååêƪƣřŶůƶƧŶƃƾƤƬţŢǀưƷřŚŝ
ŪƿŚŤƳ
ŹŵŵŹŵƥŹŵźººººŝ CB2 ŢƀººººǀƳƺĭōżƿƺººººŬţźººººŧř
ƽŚºººƷŻƹŵźºººŧřźĮƳŚºººƿŚưƳæŹřŵƺºººưƳƲǀƫŚºººƯźƟƱƺºººƯŻō
ƦººƿƽƶººƬůźƯƹŵźººƷŹŵŚººƷƁƺººƯŹŵJWH133ƞººƬŤŴƯ
ŶƃŚŝƾƯ
ƲǀƫŚƯźƟƱƺƯŻōƹŵƹ
ƽƹŹřŵƮºŬůƶºŝƍƺºŝźƯŲºſŚěƦºƿƩƹřƽƶºƬůźƯŶƃŚŝƾ
Ư
ƽŚºƷƱŹƺºƳŢǀſŚƀºůŚŝƭƹŵ ƽƶƬůźƯ ƹ ŶƃŚŝƾƯ
ƵŶƃ ƢƿŹżţ
ƕŚºŴƳƾºƠƬųűŚºƃƹƵŶºƳźǀĭŮƐºſƹŵźºƷŹŵŵŹŵŚŝƎŞţźƯ
ŚƷƁƺƯƶŝ
æåƲǀƫŚƯźƟƱƺƯŻōçƹæƽƶƬůźƯŢſřƎŞţźƯ
ŢƇźƟƱƺƯŻōƕƹźƃƹƲǀƫŚƯźƟƢƿŹżţŻřƪŞƣƶƤǀƣŵèåƪƣřŶů
ƾºưŬůžĜºſŶºƴŝŚƿƢŝŚºƐţƵŚĮƄºƿŚƯŻōƎǀŰƯŚŝŚţŶƃƵŵřŵ
ƽŶºƬūźƿŻšŹƺƇƶŝ ŶƇŹŵ çê ƲǀƫŚƯźƟŻř Ŷůřƹ çê ƩŵŚƘƯ
ĬƳźºſŻřƵŵŚƠŤºſřŚºŝƱřƺºǀůŢſřŹŢưſƾŞƤƗƽŚěƞƧƶŝ
ŚºƷƁƺºƯƲǀƫŚƯźƟƢƿŹżţŻř žě ƶƬƇŚƟǈŝŶƃƢƿŹżţ ƲǀƫƺƀƳř
ŮƐºſƦºƿƽƹŹźºŝƾƨǀŤºſǈěƽƶƳřƺŤſřƦƿƪųřŵƦţƦţ
ƶºūŹŵéêƽƶºƿƹřŻŚºŝƶƴǀŗōƦƿ ƵŶƃƶŤƃřŸĭ ƝŚƇ ƽřƶƄǀƃ
ƽŚºěƞƧƢǀƣŵƽƵŶƷŚƄƯƱŚƨƯřƶƧŵƺŝƵŶƃƶǀŞƘţƶƳřƺŤſřźƿŻ
ƢºƿŹżţŻř žěƶƬƇŚƟǈŝŵŹŵŲſŚěŵŹƹōƾƯƮƷřźƟřŹŚƷƁƺƯ
ŶºƃƾŝŚºƿŻŹřƽřƶƤǀƣŵêåƾƳŚƯŻƽƵŵƹŶŰƯƦƿƽřźŝƲǀƫŚƯźƟ
ƶºŝŹƺºŝżƯƽŚºěƲŤƟźºĭŻŚºĭŚƿƱŵŻžǀƫƱŚƯźƳšŶƯƕƺưŬƯ
160
140
ƶǀƳŚŧŵŹŵƶŝŲſŚěƱŚƯŻšŶƯ
ŹŵƲǀƫŚºƯźƟƢºƿŹżţŻřžºěŵŹŵŲſŚě řŹ ƭƹŵ ƶƬůźƯ ƱřƺƴƗƶŝ
źºŝŹŵƶºƧŵŵźºĭƾºƯƽřƶƬůźƯ
ƹŵŲſŚěƦƿƶŝźŬƴƯƲǀƫŚƯźƟ
120
100
80
60
40
*
20
*
0
Ʋ ǀ ƫ Śſ
ƹŹřŵƪººƯŚů
0.01
0.1
1
(¹³Â¸Ì¯¹³Ê¸Ì»)
źĮƳŚƿŚưƳĚģŢưſƽŚƷƱƺŤſ
ŶƷŚƃƵƹźĭŚŝƶƀƿŚƤƯŹŵƲǀƫŚƯźƟƱƺƯŻōŹŵŵŹŵŲſŚěšŶƯźŝJWH133ƞƬŤŴƯƽŚƷŻƹŵżƿƺŬţźǀŧŚţæŹřŵƺưƳ
ƱřƺºǀůìŵŹřŶƳŚŤºſřƽŚºƐųtƲǀĮƳŚǀƯźĭƱŚǀŝ
ƱƺŤſźƷŶƃŚŝƾƯƲǀƫŚƯźƟƱƺƯŻōƭƹŵ
ƽƶƬůźƯźĮƳŚƿŚưƳŢſřŹŢưſƽŚƷƱƺŤſƹƩƹřƽƶƬůźƯ
ŵƺŝƹŹřŵƪƯŚůƽƵŶƴƴƧŢƟŚƿŹŵŶƷŚƃƵƹźĭ
* = P<ååêŶƃŚŝƾƯ
ƶƬŬƯ
ƶºººƳƺĭĢǀºººƷƹŹřŵŚºººƯř
ŶºººƯōŢºººſŵƶºººŝƹŹřŵƭźĭƺºººƬǀĩ
ŹŵƽŵŹŵƾººººŝźººººŧřƶººººƳƺĭĢǀººººƷJWH133ƪººººƯŚů
ƲǀƫŚºººƯźƟƱƺºººƯŻōƭƹŵƽƶºººƬůźƯŹŵŻŹŚºººŝŵŹŵŶºººƋźºººŧř
żǀƫŚºººƳōP>ååêŵřŶºººƳƱŚƄºººƳƹŵƹƦºººƿƽƶºººƬůźƯ
ƲǀƫŚºººƯźƟƱƺºººƯŻōŹŵŵŹŵƥŹŵźºººŝŜǀƀºººƧƺƨƬſšřźºººŧř
šŹƺºƇƶºŝƭźĭƺºƬǀĩźºŝƭźºĭƾ
ºƬǀƯæƹåæååæƽŚƷŻƹŵ
Féƹèå åèíêP åíæíŵřŶƳƱŚƄƳ
ŚººŝJWH133ƢººƿŹżţƶººƧŵřŵƱŚƄººƳƶººƟźƏƦººƿ
žƳŚººƿŹřƹ
ƹƭźĭƺƬǀƧŹŵƭźĭƾƬǀƯƩƺưƘƯƽŚƷŻƹŵźŧřźĮƳŚƿŚưƳçƪƨƃ
ŻƹŵƶºººŝƶŤƀºººŝřƹƽŵŹŵƾºººŝŲºººſŚěƦºººƿƾƣŚƠºººƇƪºººųřŵ
ŜǀƀººƧƺƨƬſƭźººĭƺººƬǀƧŹŵƭźººĭƺƳŚººƳ
ULDƮººĩŹŚǀƀººŝ
řŶºººƳōŢƀºººţŽŚºººſřźºººŝŵŹřŵƩƹřƶºººƬůźƯŹŵƎºººƤƟřŹ
ƹŵƹƦººƿƽƶººƬůźƯ
ƹŵźººƷŹŵƲǀƫŚººƯźƟƱƺººƯŻōƽƹŹźººŝ
ƲƯƺººǀƳŢƀººţŽŚººſřźººŝ FCéèå æìæéP<ååååæ
ŶƃŚŝƾƯ
ƲǀƫŚƯźƟƱƺƯŻōŹŵ
źººŝƭźººĭƾ
ºƬǀƯƦººƿŻƹŵŚººŝŲººſŚěźŨƧřŶººůP<ååêŢººƴƧ
160
140
14
120
100
80
*
60
*
40
* *
* *
20
0
ϦϴϟΎγ
50
100
ƭźººĭƺƬǀƧƭźººĭƾ ƬǀƯŜǀººƀĩƺĪƬſ
200
50
100
ƭźººĭƺƬǀƧƭźººĭƾƬǀƯŜǀººƀĩƺĪƬſ
ƹƩƹřƽƶƬůźƯźĭ
ƱŚƿŚưƳĚģŢưſƽŚƷ
ŶƷŚƃƵƹźĭŚŝƶƀƿŚƤƯŹŵŵŹŵŲſŚěšŶƯźŝŜǀƀƧƺƨƬſƞƬŤŴƯƽŚƷŻƹŵżƿƺŬţźǀŧŚţçŹřŵƺưƳ
ƱƺŤſ
ŶºƃŚŝƾºƯƱřƺºǀůìŵŹřŶƳŚŤºſřƽŚºƐųtƲǀĮƳŚºǀƯźºĭƱŚǀŝ
ƱƺŤſźƷŶƃŚŝƾƯƲǀƫŚƯźƟƱƺƯŻōƭƹŵƽƶƬůźƯźĭƱŚƿŚưƳŢſřŹŢưſƽŚƷƱƺŤſ
ŵƺŝƾƨưƳƭźſƵŶƴƴƧŢƟŚƿŹŵŶƷŚƃƵƹźĭ
* = P<ååê
ƾƣŚƠºƇƪºųřŵƢºƿŹżţƶºƧŵřŵƱŚƄºƳƶƟźƏƦƿ
žƳŚƿŹřƹżǀƫŚƳō
ƾƣŚƠºƇƪºųřŵƢºƿŹżţƶºƧŵřŵƱŚƄºƳƶƟźƏƦƿ
žƳŚƿŹřƹżǀƫŚƳō
ƩƹřƽƶºƬůźƯƽřźºŝŵřŶºƳƱŚƄƳƶƬůźƯƹŵźƷŹŵƽŵŹŵƾŝźŧř
ƩƹřƽƶƬůźƯƹŵźƷŹŵƽŵŹŵƾŝźŧřƦƿƽŚƤƫřŦƗŚŝƭźĭƺƬǀĩ
ƶºƳƺĭĢǀºƷŜǀƀƧƺƨƬſƭźĭƺƬǀĩźŝƭźĭƺƳŚƳêåƹçêƽŚƷŻƹŵ
ŵƺŝP åìîìƭƹŵƽƶƬůźƯ
ƽřźŝƹP
ååëê
ƹƭźĭƺºƬǀƧźºŝƭźºĭƾºƬǀƯƽŚºƷŻƹŵŹŵ ŜǀƀºƧƺƨƬſšřźŧř
JWH133ŻřƪƇŚůƽŵŹŵƾŝƽƹŹ
źŝƭźĭƺƬǀƧźŝƭźĭƺƳŚƳ
źºŝƭźºĭƾ
ºƬǀƯçååƹæåå êå ŜǀƀƧƺƨƬſƩƺưƘƯƽŚƷŻƹŵ
ƹP<ååååæ ƱƺºƯŻōƩƹřƽƶƬůźƯ
ŹŵŶƿŵźĭƱƺƯŻōƭƹŵƹ
ƭƹŵƽƶººƬůźƯŹŵƩƺº ƧƲƯƺººǀƳƱƺººƯŻōŽŚººſřźººŝP<ååê
ƩƺƧƲƯƺǀƳƱƺƯŻōŽŚſřźŝP<ååêƹP<ååååæƱƺƯŻō
ƶƬŬƯ
15
żǀƫŚººƳōƩŚººŞƳŵƶººŝƞººƃ ƾººƬǀưƨţƱƺººƯŻōP<ååååæ
žƳŚºººƿŹřƹżǀƫŚºººƳōƲǀƫŚºººƯźƟƱƺºººƯŻōƩƹřƽƶºººƬůźƯ
Źŵ
źŧŒººƯŻƹŵƲƿźŤƄººǀŝƹŜǀƀººƧƺƨƬſƽŵŹŵƾººŝźººŧřƱŚººǀƯ
Żƹŵ ƽřźºŝ ŵźºǀĭƾ
ƯŹřźƣ ŜǀƀƧƺƨƬſ ƩƺưƘƯŻƹŵ źǀŧŚţŢŰţ
ƾŤƀº ǀƳƺĭŚŤƳōƪųřŶººţƦººƿƶººƧŵřŵƱŚƄººƳƶººƟźƏƹŵžƳŚº ƿŹřƹ
èŹřŵƺưƳ
æååŻƹŵƽřźººŝP<ååååæƭźĭƺººƬǀĩźººŝƭźººĭƾ
ººƬǀƯêå
ƭźĭƺºƬǀĩźºŝƭźĭƾ
ƬǀƯ çåå Żƹŵ ƽřźŝƹƭźĭƺƬǀƧ źŝƭźĭƾ
ƬǀƯ
100
Ʋ ǀƫ Ś ſ
Series1
Celex 50
Series4
Celex
100
Celex
200
Series5
Series3
90
P ååæìŵŹřŵŵƺūƹ ƭźĭƺƬǀĩźŝƭźĭƾ
ƬǀƯ æJWH133
JWH133ƽŵŹŵƾŝźŧřƩƹř
ƽƶƬůźƯ
ŹŵƶƧŵřŵƱŚƄƳƶƟźƏƹŵ
80
70
60
+
50
+
40
30
20
10
0
ƹŹřŵƪººƯŚů
0.1
0.01
1
(¹³Â¸Ì¯¹³Ê¸Ì»)
ƢºƿŹżţŻřƪºƇŚůƽŵŹŵƾŝźŝƭźĭƺƬǀƧźŝƭźĭƾƬǀƯçååŚţêåŜǀƀƧƺƨƬſƭźĭƺƬǀƧźŝƭźĭƾƬǀƯ
ƩƺưƘƯƽŚƷŻƹŵżƿƺŬţźǀŧŚţè ŹřƺưƳ
ŶººƃŚŝƾººƯƱřƺººǀůìŵŹřŶƳŚŤººſřƽŚººƐųtƲǀĮƳŚººǀƯźººĭƱŚººǀŝƱƺŤººſźººƷƲǀƫŚººƯźƟƱƺººƯŻōæƽƶººƬůźƯŹŵƽŹƺººſƁƺººƯŹŵJWH133
ŢƟźĭšŹƺƇ
JWH133ƭźĭƺƬǀƧźŝƭźĭƾƬǀƯ
æƽƵŶƴƴƧŢƟŚƿŹŵƵƹźĭŚŝƶƀƿŚƤƯ
+ = P<ååê
JWH133ŻƹŵƲƿźºººŤưƧƲǀºººŝƽŵŹŵƾºººŝ
ƾŤƀºººƿĥźƴǀſ
ƶººƧŵřŵƱŚƄººƳƶººƟźƏƹŵžƳŚººƿŹřƹżǀƫŚººƳōźººĮƿŵƝźººƏŻř
ŚººƷƹŹřŵƲººƿřŻřƦººƿźººƷƶººƧŵŹřŵŵƺººūƹŜǀƀººƧƺƨƬſ
ng/kgƭźĭƺºƬǀƧźºŝƭźĭƺƳŚºƳ żǀģŚºƳŹŚǀƀºŝ ƽŚƷŻƹŵźǀŧŚţ
ƭźĭƺºƬǀƧźºŝƭźĭƺƳŚƳƽŚƷŻƹŵ ƹƭźĭƺƬǀƧ ŹŵƭźĭƾƬǀƯååæ
ƵŵřŶºƳƱŚƄºƳŵƺºųŻřƽŵŹŵƾºŝźºŧřƾƿŚºƸƴţƶºŝŻƹŵƲǀưƷŹŵ
éŹřŵƺưƳP ååçƹP ååéŶƳŵƺŝ
ŢŰţJWH133 ƾƣŚƠƇƪųřŵƢƿŹżţ ŻřƪƇŚů ƽŵŹŵƾŝźŧř
ŵźºǀĭƾ
ºƯŹřźºƣƭźĭƺºƬǀƧźŝƭźĭƺƳŚƳ êå ƹ çêŜǀƀƧƺƨƬſ
ƾºŗřżƟřƮºƷźºŧř ƪųřŶţ ƦƿƶƧŵřŵƱŚƄƳ ƞƃƾƬǀưƨţƱƺƯŻō
ƶƬŬƯ
Ʋ ǀƫ Ś ſ
100
16
Ce le x 25n
Series1
Series2
90
Ce
le x 50n
Series3
70
60
50
40
30
20
+
10
+
0
ƹŹřŵƪºººƯŚů
0.01
0.1
1
( ¹//³Â¸Ì¯¹//³Ê ¸Ì»)
ƁƺºƯŹŵ JWH133ƢºƿŹżţŻřƪƇŚůƽŵŹŵƾŝźŝ
ƭźĭƺƬǀƧźŝƭźĭƺƳŚƳêåƹçêŜǀƀƧƺƨƬſżǀģŚƳŹŚǀƀŝƽŚƷŻƹŵżƿƺŬţźǀŧŚţéŹřŵƺưƳ
ƵƹźºĭŚºŝƶƀºƿŚƤƯ + = P<ååêŶºƃŚŝƾºƯƱřƺǀůìŵŹřŶƳŚŤſřƽŚƐųtƲǀĮƳŚǀƯźĭƱŚǀŝ
ƱƺŤſźƷƲǀƫŚƯźƟƱƺƯŻōæƽƶƬůźƯŹŵƽŹƺſ
ŢƟźĭšŹƺƇ
JWH133ƭźĭƺƬǀƧźŝƭźĭƾƬǀƯ
ååæƽƵŶƴƴƧ
ŢƟŚƿŹŵ
ƹJWH133ƱŚºººǀƯƾŤƀºººǀƳƺĭŚŤƳōŚºººƿƹƾºººŗřżƟřƮºººƷ
ƪººººƇŚůƽŵŹŵƾººººŝƽƹŹźººººŝŜǀƀººººƧƺƨƬſšřźººººŧř
êŹřŵƺưƳŶƄƳ
źººŧřƪųřŶººţƕƺººƳĢǀººƷƶƠǀººƃƾººƬǀưƨţƱƺººƯŻōŽŚººſřźŝ
ƵŶºººƿŵƲǀƫŚºººƯźƟƱƺºººƯŻōƭƹŵƽƶºººƬůźƯ
ŹŵŜǀƀºººƧƺƨƬſ
ƲǀƫŚºººººƯźƟƱƺºººººƯŻōƭƹŵƽƶºººººƬůźƯŹŵJWH133Żř
160
ƲSeries1
ǀƫ Ś ſ
Celex
50
Series3
Series4
Celex
100
Series5
Celex
200
140
80
120
100
80
60
40
20
0
ƹŹřŵƪºººƯŚů
0.01
0.1
1
(¹ //³Â¸Ì¯¹//³Ê/¸Ì»)
ƢƿŹżţŻřƪƇŚůƽŵŹŵƾŝźŝ
ƭźĭƺƬǀƧźŝƭźĭƾƬǀƯ
çååŚţêåŜǀƀƧƺƨƬſƭźĭƺƬǀƧźŝƭźĭƾƬǀƯ
ƩƺưƘƯƽŚƷŻƹŵżƿƺŬţźǀŧŚţêŹřŵƺưƳ
ŶƃŚŝƾƯƱřƺǀů
ìŵŹřŶƳŚŤſřƽŚƐųtƲǀĮƳŚǀƯźĭƱŚǀŝ
ƱƺŤſźƷƲǀƫŚƯźƟƱƺƯŻōçƽƶƬůźƯŹŵƽŹƺſƁƺƯŹŵ
JWH133
ƶƬŬƯ
17
Ʋģçíèå Ţſř ƶŤƟźĭŹřźƣƶƘƫŚƐƯŵŹƺƯ ƽřƵŵźŤƀĭ ƱřżǀƯ
ƽŚºƷŢƀǀƳƺĭōƩƺƯƺƳŚƳƽŚƷŢƔƬƛƶƧ ŶƳŵřŵƱŚƄƳ ƱřŹŚĪưƷƹ
ŦŰŝ
JWH133ƽŵŹŵƾººŝ
źǀŧŚººţźººƋŚůƽƶººƘƫŚƐƯŪƿŚººŤƳ
èæŶºƳřƶŤºƃřŵƞƫŚºŴƯƾºţřźŧřƹŹřŵƩƺºƯƹźƨǀƯƽŚƷŢƔƬƛ
šŚºƘƫŚƐƯŚºŝƢºŞƐƴƯƶºŬǀŤƳƲºƿřƶƧŵřŵƱŚƄƳřŹƽŹƺſƁƺƯ
ƾƫŚºůŹŵŢſřƵŶƃ ƲǀƫŚƠƨƳřƽŻŚſŚƷŹ ƂƿřżƟřŜūƺƯ ƲǀƟźƯ
COXIIƮƿżºƳōƾƇŚƈºŤųřƽƵŶºƴƴĩŹŚƸƯĨºƿƢºƿŹżţƶƧŵřŵ
ŹŵźºƋŚůƽƶºƘƫŚƐƯŪƿŚºŤƳƶºģźĭřƲƿřźŝŚºƴŝèçŢſřƵŶƃ
ƾºųźŝŵŹřŵŵƺºūƹźºƔƳƝǈŤºųřƦƿƍŚŞţŹřƲƿřŹŵŶƴĩƾ
Ư
Ʋǀºƫƹř ƾºƫƹŵƺºŞƳ ƽŶºƿŶū ƽƶºŤƟŚƿ ƭźĭƺºƬǀƧźºŝƭźĭƺƳŚƳ
ƹ(NSAID)ƽŶǀŗƹźŤºſřźºǀƛśŚƸŤƫřŶƋƽŚƷƹŹřŵƱŚƯŻƮƷ
źºŝƭźĭƺƳŚƳ ŻƹŵŚŝƶƀƿŚƤƯŹŵŜǀƀĩƺĪƬſç ĥŚƳĦǀƀĩřƺƬĪǀſ
ƁŹřżºĭřŹƽŵŹŵƾºŝźŧřƾŤƀǀƳƺĭŚŤƳōźǀŧŚţƦƿźĮƿŵšŚƘƫŚƐƯ
ƱřƺººƴƗƶººŝŚƷŶººǀŗƺƴǀŝŚƳŚƧŵřŵƱŚƄººƳ CB2 ƽŶººǀŗƺƴǀŝŚƳŚƧ
ƁŹřżĭřŹƽŵŹŵƾŝźŧřŢƿƺƤţƶƧƾţŚƘƫŚƐƯ ƹźƋŚů ƽƶƘƫŚƐƯ
Ĩºƿ ŵŚºŬƿřŜºūƺƯ ŚºƷNSAID ƹŚƷŶǀŗƺǀěřŜǀƧźţŶƳŹřŵ
ƽƶºƘƫŚƐƯŹŵƶºƧƾƫŚºůŹŵŶƃŚŝ šŚƘƫŚƐƯƱōŹŵƲǀſŚŤƯƹŶƴƿř
ƾŞƳŚºūƉŹřƺºƗƂƷŚºƧ ƶŬǀŤƳŹŵƹ ƹŹřŵ ƹŵźƷ ŻƹŵƂƷŚƧ
šƹŚºƠţŢºſřƲºƨưƯƲǀƴĤưƷ Ţſř ƶŤƟźĭŹřźƣƵŵŚƠŤſř ŵŹƺƯ
ƽƶƘƫŚƐƯŪƿŚŤƳƶƧŢſřƾƫŚůŹŵƲƿřèèƹèéŶƴƧƾƯ
ƮƷřźƟ
ƶºƧŶºƳřƵŵřŵƱŚƄºƳƲǀƄǀěšŚƘƫŚƐƯźĮƿŵƝźƏŻřŶƃŚŝƶŤƃřŵ
ƶºĩƾƫŚºůŹŵŵŵźĭƾƯ
ŹŚƸƯŜǀƀĩƺĪƬſƩƺưƘƯŻƹŵƽƶƬǀſƹ
ƲºƿřƶºƧçæçê ŶƴƿŚưƳƾ
ƯŌŚƤƫřřŹŚƷƲƿŶƳǈĭŚŤſƹźěżŤƴſƹ
żǀģŚººƳŹŚǀƀººŝƽŚººƷŻƹŵźºĮƿŵƝźººƏŻřŶºƃŚŝƾ
ºƯƽŵŹŵƾ
ºŝ
ŜǀƀºººƧƺƨƬſƹJWH133ƩƺºººưƘƯƽŚºººƷŻƹŵƽŵŹŵƾºººŝ
ƹŵƲºƿřƶƧƾƫŚůŹŵŢſřƵŵřŵƱŚƄƳJWH133ŚŝƾŗřżƟřƮƷ
źºŝƱō ƮºĩŹŚǀƀºŝ ƽŚºƷŻƹŵ ƹ ŜǀƀºƧƺƨƬſƩƺºưƘƯƽŚƷŻƹŵ
ŶƴƷŵƾưƳƱŚƄƳ
ƽźºĮƿŵŵŶºƘŤƯšŚƘƫŚƐƯŪƿŚŤƳŚŝƢŝŚƐƯźŧřƲƿřƶƧŶƳŵřŵƱŚƄƳ
ƽźǀĭƶŬǀŤƳ
ŜºǀƀƧƺƨºƬſƾŗřżºƟřƮºƷźǀºŧŚţƩŚŞºƳŵƶºŝźĭřƲƿřźºŝŚƴºŝ
ƶºƬưūŻřŚƷŶºǀŗƺǀěřçëƹçì ŶºƃŚŝƾ
ƯŚƸƳō ƮƧ ŹŚǀƀŝ ƽŚƷŻƹŵ
ƶºƧƾƫŚůŹŵŶƴƷŵƾƯ
ƂƿřżƟřřŹƪưƗƪǀƀƳŚŤěƱŚƯŻƽŶǀŗƺǀěƹř
ŹŵƲǀƫŚºƯźƟ ƱƺƯŻōŹŵ CB2 ƽƵŶƳźǀĭ ƾƇŚƈŤųř ŢƀǀƳƺĭō
ƩƺƯƺƳŚºƳƽŚºƷŢºƔƬƛƢºƿŹżţƶºƧŶºƳřƵŵřŵƱŚƄƳŢƴƯŶƯƺǀƫƹř
ƱŚƄƳƲǀƴĤưƷƶƘƫŚƐƯƲƿřŪƿŚŤƳæêŶƃŚŝƾ
ƯƾƬŞƣƵŶƃƭŚŬƳř
ƱōƽŻŚºſŚƷŹƂƷŚºƧŜºūƺƯƩƺƯƾƬǀƯƽŚƷŢƔƬƛżƿƺŬţƶƧ
ŹŚºƸƯřŹJWH133ŻřƪºƇŚůƽŵŹŵƾºŝźºŧřŜǀƀºĩƺĪƬſ
ƹŹřŵƦƿżǀģŚƳŹŚǀƀŝŻƹŵƹƩƺưƘƯƽŚƷŻƹŵŵŚƌŤƯźǀŧŚţŵŹƺƯ
żƿƺºŬţŻřƪºƇŚůƽŵŹŵƾºŝŹŵƾºŗřżƟřƮºƷźŧřƦƿšŚƤǀƤŰţ
ƽƵŶºƴƴĩŹŚºƸƯĨƿƩƺưƘƯŻƹŵŵŚƌŤƯšřźŧřƶƧŵƺŝƽřƶƘƫŚƐƯ
ƾºųźŝƶƧƾƫŚůŹŵæëƹæìŶƳřƵŵƺưƳ
ƁŹřżĭřŹŚƷŶǀŗƺƴǀŝŚƳŚƧ
ƽŚºƷƵŶºƳźǀĭƦºƿźŰţ ŻřƪºƇŚůƽŵŹŵƾºŝźŝ řŹ Ʊō ƭźĭƺƬǀƧ
ƱŚºǀƯƶºŬǀŤƳ ƝǈŤºųřƲºƿř ŢºſřƲºĪưƯæíçåŶƳřƵŵźƧ
ŚƷŶǀŗƺǀěƹřŚŝƽřƶŝŚƄƯƦƿĥƺƫƺƧŚƯŹŚƟƅřƺųŵŹŵŶƋ ƽŚƷƹŹřŵ
ƱƺºĤưƷ ƾƇŚƈºŤųřźǀƛNSAID ŵźŝŹŚºĩŻř ƾºƃŚƳ ŶƳřƵŵźƧ
ƱŚƨƯřƕƺƋƺƯƲƿřƶƧŢſřƵŶƃƽŵŹŵƾŝŹŵƾŗřżƟřƮƷƪųřŶţ
(celecoxib)COXIIƾŝŚºŴŤƳřƽƵŶºƴƴĩŹŚºƸƯƦºƿ źƋŚů
řŹŶƳƺºƃƾºƯƵŵŚƠŤºſřƾƿŚºƸƴţƶºŝƶºƧƾƳŚƯŻŚŝƶƀƿŚƤƯŹŵŚƸƳō
ŢºƫŚųŵƶºƘƫŚƐƯƹŵƲƿřŹŵƶŤƟŹŹŚƧƶŝƱřƺǀůƽƶƳƺĭƹžƴū
ƶºŝŚƷŶºǀŗƺƴǀŝŚƳŚƧŻřƪºƇŚůƽŵŹŵƾºŝźºŧřƶƧŶƷŵƾƯ
ƱŚƄƳŚƯ
ƦƿźŰţřŹ ŵřŻƱƹŹŵ ŶǀſřƦǀƳƹŶǀƃřŹō ƽŻŚſŚƷŹ ŚƷŶǀŗƺƴǀŝŚƳŚƧ
źºŧřŶºūřƹƾŗŚºƸƴţƶºŝƶŤƟŹŹŚƧƶŝŻƹŵŹŵŚƷƹŹřŵƲƿřƽƹŵźƷ
źǀŧŚºţƱŚǀƯƾŤƀǀƳƺĭŚŤƳōƪųřŶţƽƵŶƴƴƧƶǀūƺţŶƳřƺţƾƯƕƺƋƺƯ
ƪųřŶºţĨºƿƽŹƺºſƁƺƯŹŵƲǀƫŚƯźƟƱƺƯŻōŹŵŜǀƀĩƺĪƬſ
źºƋŚů ƽƶƘƫŚƐƯ ŪƿŚŤƳ ŽŚſřźŝŶƃŚŝƭźĭƺƬǀƧŹŵƭźĭƾƬǀƯ
ŵƺºųŻřƽŵŹŵƾºŝźºŧřƾŗŚƸƴţƶŝżǀģŚƳŹŚǀƀŝƽŚƷŻƹŵŹŵƹŹřŵ
ŵŚƌºŤƯźǀŧŚţƦƿƽƶƬůźƯŹŵJWH133ŻřƪƇŚůƽŵŹŵƾŝ
ŵŚƌŤƯŚƷƹŹřŵƾųźŝƩƺưƘƯƽŚƷŻƹŵźŧřŶƳřƵŵřŵƱŚƄƳƶƧŢſř
ƶºŝŚºƸƳōƮºĩŹŚǀƀŝƽŚƷŻƹŵ ƽĥƺƫƺƧŚƯŹŚƟƶƧŶƴŤƀƷƾƿŚƷƹŹřŵ
ƶƬŬƯ
źƨƄţƹźƿŶƤţ
ƽřƶºƟźůƽźºŤƧŵƶºƯŚƳƱŚƿŚěƦƿŪƿŚŤƳŻřƾƄŴŝƶƫŚƤƯƲƿř
ƵŚĮƄƳřŵƾƄƷƹĦěƭźŤŰƯŢƳƹŚƘƯƝźƏŻřƶƧŶƃŚŝƾƯƾƨƃżě
ŢºƿŚưůŵŹƺºƯśƺƈºƯŭźƏšŹƺƇƶŝƱŚŬƳŻƾƨƃżěƭƺƬƗ
ŜºţřźƯ ƶƫŚƤƯ ƱŚĭŶƴƀƿƺƳƶƬǀſƹƲƿŶŝ
ƶƧ ŢſřƶŤƟźĭŹřźƣƾƫŚƯ
ŶƳŹřŵƾƯ
ŻřźŝřřŹŵƺųƾƳřŵŹŶƣ
18
ƾƴǀƫŚººŝƱŚººƯŻƮººƷŵźŝŹŚººƧƦººƿƱřƺººƴƗƶººŝŚƷŶººǀŗƺƴǀŝŚƳŚƧƹ
ƞººƬŤŴƯƽŚººƷŻƹŵŻřƪººƇŚůŪƿŚººŤƳƶººŝŢººſřƭŻǇƮǀººƃŚŝ
ƭŚººŬƳřũŚººŤŰƯźººƯřƲººƿřƶººƧƮǀººƃŚŝƶŤººƃřŵƶººūƺţƹŹřŵ
ƽŚººƷƁƹŹƹƾƳřƺººǀůźººĮƿŵƽŚººƷƶººƳƺĭŹŵźŤƄººǀŝšŚººƘƫŚƐƯ
ƵŶººƃƩźººŤƴƧƾƴǀƫŚººŝšŚººƘƫŚƐƯżººǀƳƹŵŹŵƾŝŚººƿŻŹřźººĮƿŵ
ŶƃŚŝƾƯ
ƖŝŚƴƯ
Molecular
characterization
of
a
peripheral
1- Rodríguez de Fonseca F, Del Arco I,
receptor forcannabinoids. Nature.1993; 365: 61-5.
Bermudez-Silva FJ, Bilbao A, Cippitelli A,
8- Huffman JW, Liddle J, Yu S, et al. 3-(1',1'-
Navarro
system:
Dimethylbutyl)-1-deoxy-delta8-THC and related
physiology and pharmacology. Alcohol Alcohol.
compounds: synthesis of selective ligands for the
2005; 40: 2-14.
CB2 receptor. Bioorg Med Chem. 1999; 7:
2- Dogrul A, Gul H, Akar A, Yildiz O, Bilgin F,
2905-14.
Guzeldemir
cannabiniod
9- Dubuisson D, Dennis SG. The formalin test: a
antinociception: synergy with spinal sites. Pain.
quantitative study of the analgesic effects of
2003; 105: 11-6.
morphine, meperidine, and brain stem stimulation
3- Yesilyurt O, Dogrul A, Gul H, et al. Topical
in rats and cats. Pain. 1977; 4: 161-74.
cannabinoid
10- Tjølsen A, Berge OG, Hunskaar S, Rosland
M.
The
endocannabinoid
E.
Topical
enhances
topical
morphine
antinociception. Pain. 2003; 105: 303-8.
JH, Hole K. The formalin test: an evaluation of
4- Yeºilyurt O, Dogrul A. Lack of cross-tolerance
the method. Pain. 1992; 51: 5-17.
to
systemic
11- Hunter SA, Burstein S, Renzulli L. Effects of
and topical cannabinoids in morphine-tolerant
cannabinoids on the activities of mouse brain
mice.
lipases. Neurochem Res. 1986; 11: 1273-88.
the
antinociceptive
Neurosci
Lett.
effects
2004;
of
371:
122-7.
5- Dewey WL. Cannabinoid pharmacology.
12-
Pharmacol Rev. 1986; 38: 151-78.
mediation in cannabinoid stimulated arachidonic
6- Matsuda LA, Lolait SJ, Brownstein MJ, Young
acid mobilization and anandamide synthesis.
AC, Bonner TI. Structure of a cannabinoid
Life Sci. 1997; 60: 1563-73.
receptor and functional expression of the cloned
13- Khalilzadeh A, Tayebi Meybodi K, Vakili
cDNA.
Nature.
1990;
346:
561-4.
7- Munro S, Thomas KL, Abu-Shaar M.
Zarch
Hunter
A,
SA,
Burstein
Zarrindast
MR,
SH.
Receptor
Djahanguiri
B.
Discrepancy between effects of milligram and
ƶƬŬƯ
19
nanogram doses of a COX-2 inhibitor (celecoxib)
model of neuropathic pain. Neuropharmacology.
on morphine state-dependent memory of passive
2006; 50: 814-23.
avoidance in mice. Brain Res Bull. 2005; 67:
21- Burstein S, Hunter SA. Prostaglandins and
443-7.
cannabis-VIII. Elevation of phospholipase activity
14- Dickenson AH, Sullivan AF. Peripheral
by cannabinoids in whole cells and subcellular
origins and central modulation of subcutaneous
preparations. J Clin Pharmacol. 1981; 21: 240-8S.
formalin-induced activity of rat dorsal horn
22-
neurons. Neurosci Lett. 1987; 83: 207-11.
Prostaglandins and cannabis. XII. The effect of
15- Ibrahim MM, Rude ML, Stagg NJ, et al. CB2
cannabinoid on the synthesis of prostaglandins by
cannabinoid
human lung fibroblast. Mol Pharmacol. 1983; 23:
receptor
mediation
of
Burstein
S,
Hunter
SA,
Ozman
K.
antinociception. Pain. 2006; 122: 36-42.
121-6.
16- Gühring H, Hamza M, Sergejeva M, et al. A
23-
role for endocannabinoids in indomethacin-
tetrahydrocannabinol
induced spinal antinociception. Eur J Pharmacol.
prostaglandins in the rat. Psychopharmacology.
2002; 454: 153-63.
1986; 90: 499-502.
17- Guindon J, De Léan A, Beaulieu P. Local
24-
interactions
prostaglandins
between
anandamide,
an
Bhattacharya
Laviolette
SK.
(THC)
M,
increases
Belanger
in
Delta9-
J.
brain
Role
of
marihuana-induced
endocannabinoid, and ibuprofen, a nonsteroidal
bronchodilation. Respiration. 1986; 49: 10-5.
anti-inflammatory
25- Hunter SA, Audette CA, Burstein S. Elevation
drug,
in
acute
and
inflammatory pain. Pain. 2006; 121: 85-93.
of brain prostaglandin E2 levels in rodents by
18- Yamaguchi T, Shoyama Y, Watanabe S,
delta-1-tetrahydrocannabinol.
Yamamoto T. Behavioral suppression induced by
Leukot Essent Fatty Acids. 1991; 43: 185-90.
cannabinoids
the
26- Shen KF, Crain SM. Ultra-low doses of
arachidonic acid cascade in rats. Brain Res. 2001;
naltrexone or etorphine increase morphine's
889: 149-54.
antinociceptive
19- Anikwue R, Huffman JW, Martin ZL, Welch
tolerance/dependence in mice. Brain Res. 1997;
SP. Decrease in efficacy and potency of
757: 176-90.
nonsteroidal anti-inflammatory drugs by chronic
27- Jonas W, Lin Y, Tortella F. Neuroprotection
delta(9)-tetrahydrocannabinol administration. J
from glutamate toxicity with ultra-low dose
Pharmacol Exp Ther. 2002; 303: 340-6.
glutamate.
20- Guindon J, Beaulieu P. Antihyperalgesic
28- Crain SM, Shen KF. Ultra-low concentrations
effects of local injections of anandamide,
of naloxone selectively antagonize excitatory
ibuprofen, rofecoxib and their combinations in a
effects of morphine on sensory neurons, thereby
is
due
to
activation
of
potency
Neuroreport.
Prostaglandins
and
2001;
attenuate
12:
335-9.
ƶƬŬƯ
increasing
and
action potential of mouse sensory ganglion
attenuating tolerance/dependence during chronic
neurons in dissociated cell cultures. Brain Res.
co-treatment. Proc Natl Acad Sci USA. 1995; 92:
1988; 462: 372-7.
10540-4.
32- Olive MF, Maidment NT. Opioid regulation
29- Crain
its
SM,
antinociceptive
Shen
KF.
potency
20
Acute
thermal
of pallidal enkephalin release: bimodal effects of
hyperalgesia elicited by low- dose morphine in
locally administered mu and delta opioid agonists
normal mice is blocked by ultra-low dose
in freely moving rats. J Pharmacol Exp Ther.
naltrexone, unmasking potent opioid analgesia.
1998; 285: 1310-6.
Brain Res. 2001; 888: 75-82.
33- Raffa RB. Pharmacology of oral combination
30- Powell KJ, Abul-Husn NS, Jhamandas A,
analgesics: Rational therapy for pain. J Clin
Olmstead MC, Beninger RJ, Jhamandas K.
Pharm Ther. 2001; 26: 257-64.
Paradoxical effects of the opioid antagonist
34- Van Dyke T, Litkowski LJ, Kiersch TA,
naltrexone on morphine analgesia, tolerance, and
Zarringhalam NM, Zheng H, Newman K.
reward in rats. J Pharmacol Exp Ther. 2002; 300:
Combination oxycodone 5 mg/ibuprofen 400 mg
588-96.
for the treatment of postoperative pain: a double-
31- Chen GG, Chalazonitis A, Shen KF, Crain
blind, placebo- and active-controlled parallel-
SM. Inhibitor of cyclic AMP-dependent protein
group study. Clin Ther. 2004; 6: 2003-14.
kinase blocks opioid-induced prolongation of the
ƶƬŬƯ
21
Interaction between JWH133-induced Antinociception and two extreme Doses of
Celecoxib
Ghahremani Z1, Rezaee-Kalaj S1, Zarrindast MR2, Djahanguiri B2, Jafari MR1
1
Dept. of Physiology and Pharmacology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
2
Dept. of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Corresponding Author: Jafari MR. Dept. of Physiology and Pharmacology, School of Medicine, Zanjan University of
Medical Sciences, Zanjan, Iran.
Email: [email protected]
Received: 31 Aug 2009
Accepted: 19 Sep 2009
Background and Objective: JWH133 is known to have cannabinoid-2 (CB2) receptor agonist properties.
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is also known to have antinociceptive
properties. Endocannabinoids produce analgesia possibly through cyclooxygenase (COX) pathway. The aim
of the present work was: to study the effect of celecoxib on JWH133 induced antinociception and to
compare the effects of two different dose ranges of celecoxib (mg/kg and nano g/kg) on the JWH133
antiniciceptive effect.
Materials and Methods: We have studied the possible interaction of administration of mg/kg (50-200
mg/kg) and Ultra-Low Dose (ULD) (25 and 50 ng/kg) of celecoxib on the antinociceptive effect of
intraperitoneal (i.p.) injection of JWH133 using formalin test in mice.
Results: JWH133 (0.01, 0.1 and 1 mg/kg) induced antinociceptive effect just in phase I of the formalin test.
Celecoxib (50-200 mg/kg) and its ULD (25 and 50 ng/kg) attenuated and potentiated, JWH133 induced
antinociception, respectively.
Conclusions: It is concluded that JWH-133 induced antinociception is modulated by celecoxib and mg/kg
doses of celecoxib showed opposite effects compare to its ultra-low doses.
Key words: JWH133, Antinociception, Celecoxib, Ultra-Low Dose (ULD), Mice
ƶƬŬƯ

Interaction between JWH133-induced Antinociception and two

Transkrypt

Podobne dokumenty

تاثیر تزریق داخل صفاقی نانو ذرات مولیبدن بر تست‌های عملکردی

ſŹźŝ ƾ ŝǀƱĥ ƱŚ ŚƷƽ ƹ ġŹŚƣ Źŵ ŻřŹŚºě ƪºƯŚƘţ ƭŚĮƴƷ ƿŤƾ Śºŝ ź